Rates of adverse events, complications and unfavorable outcomes were similar between intravitreal anti-VEGF agents and LPC in high quality RCTs like RAINBOW [6] and BEAT-ROP [5]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.